FDA at last approves weight-management drug Contrave

11 September 2014
fda-big

After considerable delay, the US Food and Drug Administration late yesterday finally granted approval for the weight-loss drug Contrave (naltrexone and bupropion) extended-release tablets.

Contrave will be marketed in the USA by the US subsidiary of Japan’s largest drugmaker Takeda Pharmaceutical (TYO: 4502), under license from originator Orexigen Therapeutics (Nasdaq: OREX). Shares of Orexigen were barely moved by the news, rising just 0.85% to $5.90 in after-hours trading. However, by mid-morning the stock had fallen 10% to $5.31.

The drug is approved for use in adults with a body mass index (BMI) of 30 or greater (obesity) or adults with a BMI of 27 or greater (overweight) who have at least one weight-related condition such as high blood pressure (hypertension), type 2 diabetes, or high cholesterol (dyslipidemia).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical